Loading…
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $308M | $-85M | $-96M | $-58M | -26.1% | 37.2% | 4.5% |
| 2024 | $224M | $-82M | $-91M | $-104M | -22.7% | 64.8% | -13.7% |
| 2023 | $136M | $-98M | $-106M | $-133M | -37.7% | 81.6% | 21.5% |
| 2022 | $75M | $-79M | $-87M | $-83M | -44.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 75.01 | 136.19 | 224.50 | 308.05 |
| Operating Revenue | - | 75.01 | 136.19 | 224.50 | 308.05 |
| Cost Of Revenue | - | 37.93 | 65.14 | 87.40 | 111.83 |
| Gross Profit | - | 37.08 | 71.05 | 137.10 | 196.23 |
| Operating Expense | - | 117.81 | 180.22 | 233.71 | 300.08 |
| Research And Development | - | 28.98 | 48.45 | 62.30 | 71.28 |
| Selling General And Administration | - | 88.83 | 131.77 | 171.42 | 228.81 |
| Total Expenses | - | 155.74 | 245.36 | 321.11 | 411.91 |
| Operating Income | - | -80.72 | -109.17 | -96.61 | -103.86 |
| Total Operating Income As Reported | - | -80.72 | -109.17 | -96.61 | -103.86 |
| EBITDA | - | -79.13 | -98.02 | -81.63 | -85.41 |
| Normalized EBITDA | - | -75.59 | -97.91 | -81.51 | -85.41 |
| EBIT | - | -81.97 | -101.82 | -86.86 | -91.80 |
| Interest Income | - | 2.50 | 7.55 | 10.90 | 12.22 |
| Interest Expense | - | 5.18 | 4 | 4.18 | 3.59 |
| Net Interest Income | - | -2.69 | 3.56 | 6.71 | 8.63 |
| Other Non Operating Income Expenses | - | -0.20 | -0.10 | -1.03 | -0.16 |
| Other Income Expense | - | -3.74 | -0.20 | -1.14 | -0.16 |
| Interest Income Non Operating | - | 2.50 | 7.55 | 10.90 | 12.22 |
| Interest Expense Non Operating | - | 5.18 | 4 | 4.18 | 3.59 |
| Net Non Operating Interest Income Expense | - | -2.69 | 3.56 | 6.71 | 8.63 |
| Pretax Income | - | -87.15 | -105.82 | -91.04 | -95.38 |
| Tax Provision | - | - | 0.08 | 0.37 | 0.19 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -87.15 | -105.90 | -91.41 | -95.57 |
| Net Income From Continuing And Discontinued Operation | - | -87.15 | -105.90 | -91.41 | -95.57 |
| Net Income From Continuing Operation Net Minority Interest | - | -87.15 | -105.90 | -91.41 | -95.57 |
| Net Income | - | -87.15 | -105.90 | -91.41 | -95.57 |
| Net Income Common Stockholders | - | -87.15 | -105.90 | -91.41 | -95.57 |
| Net Income Including Noncontrolling Interests | - | -87.15 | -105.90 | -91.41 | -95.57 |
| Normalized Income | - | -83.61 | -105.79 | -91.30 | -95.57 |
| Diluted NI Availto Com Stockholders | - | -87.15 | -105.90 | -91.41 | -95.57 |
| Basic Average Shares | - | 44.40 | 47.26 | 52.12 | 55.54 |
| Diluted Average Shares | - | 44.40 | 47.26 | 52.12 | 55.54 |
| Reconciled Depreciation | - | 2.84 | 3.81 | 5.23 | 6.39 |
| Reconciled Cost Of Revenue | - | 37.93 | 65.14 | 87.40 | 111.83 |
| Total Unusual Items | 0.20 | -3.54 | -0.11 | -0.11 | - |
| Total Unusual Items Excluding Goodwill | 0.20 | -3.54 | -0.11 | -0.11 | - |
| Special Income Charges | 0 | -3.26 | 0 | 0 | - |
| Other Special Charges | - | 3.26 | - | - | - |
| Gain On Sale Of Security | 0.20 | -0.28 | -0.11 | -0.11 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporationthis co. | PRCT | $1.5B | -16.08 | 4.20 | -26.1% | -15.56 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.6B | -10.99 | 5.21 | -47.4% | -8.97 |
| agilon health, inc. | AGL | $1.6B | - | 12.54 | -308.8% | - |
| Nurix Therapeutics, Inc. | NRIX | $1.6B | - | 2.93 | -49.1% | - |
| Sonida Senior Living, Inc. | SNDA |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.6B |
| -22.19 |
| -142770.48 |
| 643445.5% |
| 96.78 |
| Vir Biotechnology, Inc. | VIR | $1.5B | - | 2.02 | -57.2% | - |
| ArriVent BioPharma, Inc. | AVBP | $1.5B | - | 5.02 | -54.1% | - |
| AnaptysBio, Inc. | ANAB | $1.5B | - | 40.41 | -35.6% | 17.42 |
| STAAR Surgical Company | STAA | $1.5B | -18.48 | 4.32 | -23.4% | -36.86 |
| Peer Median | - | -18.48 | 4.67 | -48.3% | 4.22 | |